Christopher Pierce, EVP and Chief of Business Oper at Prelude Therapeutics Inc (PRLD), sold 828 shares at $40.08 ($33K) on 2021-04-07, disclosed to the SEC on 2021-04-09.
Scheduled sale ($33k) by EVP and Chief of Business Oper under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| Filing → |
| PRLD | SELL | 2021-04-15 | $8K | — | Filing → |
| PRLD | BUY | 2020-09-29 | $71K | — | Filing → |